DEMO DEMO

Name: DEMO DEMO
Date of Birth: 00-00-0000
Biological Sex: Male
Age: 52
Height: 70 inches
Weight: 150 lbs
Fasting:

Telephone: 000-000-0000
Street Address:
Email:

FINAL REPORT

Accession ID: 2526442383

Provider Information

Practice Name: DEMO CLIENT, MD
Provider Name: DEMO CLIENT, MD
Phlebotomist: 0

Telephone: 000-000-0000
Address: 3521 Leonard Ct, Santa Clara, CA 95054

Report Information

Current Result | Previous Result | In Control | Moderate | Risk

Specimen Information

Sample Type	Collection Time	Received Time	Report	Final Report Date
Serum	Local 2026-03-29 17:00	2026-03-30 14:58 (PDT)	Vibrant America - P2	2026-07-08 13:38 (PDT)

SAMPLE

Regulatory Statement : Tests indicated with an asterisk (*) were developed, and its performance characteristics determined by Vibrant America Clinical Laboratory. It has not been cleared or approved by the US Food and Drug Administration. Tests indicated with an asterisk (¹) were developed, and its performance characteristics determined by Vibrant Genomics LLC. It has not been cleared or approved by the US Food and Drug Administration.

VibrantAmerica
3521 Leonard Ct, Santa Clara, CA 95054
1-866-364-0963 | support@vibrant-america.com | www.vibrant-america.com

TNP Test not performed

R&L Refer to risks and limitations at the end of report

Notes Refer to Lab notes at the end of the table

Total Immunoglobulins

No markers are outside the normal reference range

SAMPLE

Patient Name: **DEMO DEMO**
Date of Birth: **00-00-0000** Accession ID: **2526442383**
Service Date: **Local 2026-03-29 17:00**

Vibrant America - All Markers

Total Immunoglobulins

Test Name	Current	Previous	Result	Reference
Total IgA (mg/dL)	210.0		0 60 356	61.0-356.0
Total IgG (mg/dL)	815.0		0 766 1590	767.0-1590.0
Total IgE (IU/ml)	16.60		0 87	≤87.0
Total IgM (mg/dL)	61.0		0 44 281	45.0-281.0

SAMPLE

DEMO DEMO

Name: DEMO DEMO
Date of Birth: 00-00-0000
Biological Sex: Male
Age: 52
Height: 70 inches
Weight: 150 lbs
Fasting:

Telephone: 000-000-0000
Street Address:
Email:

FINAL REPORT

Accession ID: 2526442383

Provider Information

Practice Name: DEMO CLIENT, MD
Provider Name: DEMO CLIENT, MD
Phlebotomist: 0

Telephone: 000-000-0000
Address: 3521 Leonard Ct, Santa Clara, CA 95054

Specimen Information

Sample Type	Collection Time	Received Time	Report	Final Report Date
Serum	Local 2026-03-29 17:00	2026-03-30 14:58 (PDT)	Immune Zoomer - P5	2026-07-08 13:38 (PDT)

SAMPLE

Disclaimer: Vibrant provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing or otherwise using the report or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to these terms, you shall not access or use the report .

VibrantWellness
3521 Leonard Ct, Santa Clara, CA 95054
1-866-364-0963 | support@vibrant-america.com | www.vibrant-wellness.com

TNP Test not performed

R&L Refer to risks and limitations at the end of report

Notes Refer to Lab notes at the end of the table

VibrantWellness

Immune Zoomer

Redefining Early Immune Detection

The Immune Zoomer is a comprehensive blood test designed to provide a deeper look into immune health beyond standard ANA or single-antibody screens. It measures over 60 autoantibodies across key systems - including gut, thyroid, pancreas, joints, skin, nervous system, eye/retina, and more - revealing hidden drivers of immune dysregulation for earlier detection and personalized prevention strategies.

It helps identify risks for conditions such as rheumatoid arthritis, Hashimoto's thyroiditis, type 1 diabetes, celiac disease, lupus, skin disorders, and systemic autoimmunity, offering actionable insights for diet, lifestyle, trigger avoidance, and treatment planning.



SAMPLE

Immune Zoomer

INTRODUCTION

Vibrant Wellness is pleased to present Immune Zoomer to support healthy lifestyle choices in consultation with your healthcare provider. The Immune Zoomer provides a semi quantitative assessment of IgG autoantibodies across multiple organ systems, including gut, thyroid, pancreas, joints, skin, nervous system, eye, blood vessels, liver, kidney, muscular system, and systemic autoimmune markers including ANA, thyroglobulin (TG), thyroid peroxidase (TPO), and high-sensitivity C-reactive protein (hsCRP). Results are intended to be interpreted by healthcare providers to guide personalized wellness strategies informed by insights into immune system activity, autoantibody presence, and systemic inflammation.

Methodology

The Immune Zoomer is a semiquantitative assay that detects IgG antibodies in human serum for the Immune Zoomer antibodies with multiplexed chemiluminescence immunoassay (CLIA) methodology. For Anti-CCP, Vibrant uses the ELISA methodology. The testing method for ANA and dsDNA is an indirect immunofluorescence assay (IFA) manufactured by EUROIMMUN and performed on the EUROPattern system. For Thyroid and Inflammation markers, Vibrant uses FDA approved Roche Cobas platform.

Interpretation of Report

The Immune Zoomer Summary provides concise information by representing the list of antigens with positive serology antibody titers that are outside the normal reference range. Reference ranges have been established using a cohort of 192 apparently healthy adults over 18 years of age, and pediatric reference ranges are not available. While the summary table provides a quick snapshot of the analytes tested, providers are encouraged to review the comments provided following the summary for a detailed description and significance of the analytes tested.

This section is followed by a complete list of all analytes tested for all antigen markers. For antibody results, the classification of Green denotes a result that is within the normal reference range, the classification of Yellow denotes a result that is moderately elevated titer with respect to the reference range and the classification of Red denotes a result that is elevated with respect to the normal reference range. Additionally, the previous value (if available) is also indicated to help check for improvements every time the test is ordered. The reference metric, used to establish the reference range, is listed to the right of the reference range illustration (see image below) As with all testing, results should be interpreted considering a patient's history, physical examination, and/or results of other diagnostic testing.



This is followed by a complete list of all analytes tested for all antigen markers. For antibody results, the classification of Green denotes a result that is within the normal reference range, the classification of Yellow denotes a result that is moderately elevated titer with respect to the reference range and the classification of Red denotes a result that is elevated with respect to the normal reference range. Additionally, the previous value (if available) is also indicated to help check for improvements every time the test is ordered. As with all testing, results should be interpreted considering a patient's history, physical examination, and/or results of other diagnostic testing.

Please note: It is important that you discuss any modifications to your diet, exercise, drug, and/or nutritional supplementation with your healthcare provider before making any changes. Antibody titers do not indicate the presence or absence of infection, the diagnosis of which should be made based upon a thorough evaluation of clinical history.

Regulatory Disclaimer: This test was performed by Vibrant America Clinical Laboratory at 3521 Leonard Ct, Santa Clara, CA 95054 (CLIA No. 05D2078809, CAP No. 8970308). This test was developed, and its performance characteristics determined, by Vibrant America Clinical Laboratory. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

Immune Zoomer - Summary

Immune Zoomer

Gut	Current	Previous	Result	Reference
Tissue transglutaminase (Anti-tTG IgA)	0.99		0 0.94 1.05	≤0.94

CLINICAL SIGNIFICANCE
Marker for celiac disease

ASSOCIATED DAMAGE
Autoimmune damage to intestinal tissue, resulting in villous atrophy and malabsorption

SUGGESTED SUPPLEMENTS
Synbiotic: Synbiotic supplements decrease Anti - Tissue transglutaminase (tTG) levels by modulating gut microbiota, enhancing intestinal barrier function, and reducing inflammation.

Joints/Arthritis	Current	Previous	Result	Reference
Collagen type II	3.45		0 1 1.25	≤1.0

CLINICAL SIGNIFICANCE
Specific for rheumatoid arthritis

ASSOCIATED DAMAGE
Immune-mediated destruction of joint cartilage, leading to progressive joint damage and deformity

SUGGESTED SUPPLEMENTS
Vitamin E: Vitamin E supplements used on a regular basis can help individuals with RA reduce joint discomfort, edema, and stiffness.

Rheumatoid Factor (RF) (IU/mL)	25.0		0 14	≤14.0

CLINICAL SIGNIFICANCE
Diagnostic for rheumatoid arthritis

ASSOCIATED DAMAGE
Chronic inflammation of synovial joints, leading to joint damage, deformity, and disability

SUGGESTED SUPPLEMENTS
Omega-3 PUFAs: Omega-3 PUFAs reduce anti-RF antibodies by modulating immune responses and decreasing inflammation through the production of anti-inflammatory eicosanoids.

Dietary fiber mixture: Dietary Fiber Mixture enhances gut health and immune function by promoting beneficial gut microbiota and increasing the production of short-chain fatty acids, which can modulate systemic immune responses.

Echinacea extract: Echinacea Extract boosts the immune system and reduces anti-RF antibodies by enhancing phagocytosis and stimulating the activity of immune cells like macrophages and natural killer cells.

Glucosamine, chondroitin and methyl sulfonylmethane (GCM): Glucosamine, Chondroitin, and Methylsulfonylmethane (GCM) reduces anti-RF antibodies by providing anti-inflammatory effects and supporting joint health through the inhibition of pro-inflammatory cytokines and enzymes.

© Vibrant America Clinical Laboratory (CLIA No. 05D2078809) | 3521 Leonard Ct, Santa Clara, CA 95054
Laboratory Director: Dr. Claude O. Burdick, M.D. | 1-866-364-0963 | Support@vibrant-wellness.com | www.vibrant-wellness.com

Immune Zoomer - Summary

Immune Zoomer

Joints/Arthritis	Current	Previous	Result	Reference
Citrullinated Peptide Antibodies (CCP3)	21.1		0 19.9 39.9	≤19.9

CLINICAL SIGNIFICANCE
Highly specific for rheumatoid arthritis

ASSOCIATED DAMAGE
Increased joint inflammation, erosion of cartilage and bone, leading to progressive joint destruction

SUGGESTED SUPPLEMENTS
Omega -3 Fatty acids: Omega-3 fatty acid supplements decrease anti-cyclic citrullinated peptide (CCP) levels by reducing inflammation through the inhibition of pro-inflammatory cytokines and modulation of immune response pathways.

Systemic Autoimmune	Current	Pattern	Titer	Previous	Pattern	Titer
Antinuclear Antibodies (ANA)	POSITIVE	Homogeneous	1:320			

CLINICAL SIGNIFICANCE
Hallmark of systemic autoimmune diseases (e.g., SLE)

ASSOCIATED DAMAGE
Autoimmune attack on various tissues and organs, resulting in systemic inflammation and tissue damage

SUGGESTED SUPPLEMENTS
Vitamin D: Vitamin D decreases ANA antibodies by modulating the immune response and reducing autoimmunity.

Inflammation	Current	Previous	Result	Reference
hsCRP	7.4		0 0.9 3	≤0.9

CLINICAL SIGNIFICANCE
Sensitive marker for systemic inflammation. Elevated levels are seen in active autoimmune conditions and has been used to monitor disease activity and treatment response

ASSOCIATED DAMAGE
Marker of inflammatory processes and not specific to any particular autoimmune condition. Should be intepreted alongside other clinical and lab findings

Patient Name: **DEMO DEMO**
Date of Birth: **00-00-0000** Accession ID: **2526442383**
Service Date: **Local 2026-03-29 17:00**

Immune Zoomer - All Markers

Immune Zoomer

Blood Vessels	Current	Previous	Result	Reference
Beta-2 Glycoprotein I (β2GPI)	0.42		0 1 1.25	≤1.0
Cardiolipin	<0.25		0 1 1.25	≤1.0
Proteinase 3 (ANCA)	0.32		0 1 1.25	≤1.0
Central Nervous System	**Current**	**Previous**	**Result**	**Reference**
Myelin Basic Protein (MBP)	0.37		0 1 1.25	≤1.0
Dry Eyes and Mouth	**Current**	**Previous**	**Result**	**Reference**
SSA 52kDa	0.85		0 1 1.25	≤1.0
SSA 60kDa	<0.25		0 1 1.25	≤1.0
SSB	0.26		0 1 1.25	≤1.0
α-fodrin	0.59		0 1 1.25	≤1.0
Eye	**Current**	**Previous**	**Result**	**Reference**
Aquaporin-4 (AQP4)	0.91		0 1 1.25	≤1.0
Interphotoreceptor retinoid-binding protein (IRBP, RBP3)	<0.25		0 1 1.25	≤1.0
Gut	**Current**	**Previous**	**Result**	**Reference**
Parietal cell antibodies (PCA)	<0.25		0 1 1.25	≤1.0
Anti S. cerevisiae antibody (ASCA)	0.65		0 1 1.25	≤1.0
Tissue transglutaminase (Anti-tTG IgG)	0.56		0 0.94 1.05	≤0.94
Tissue transglutaminase (Anti-tTG IgA)	0.99		0 0.94 1.05	≤0.94
Deaminated gliadin (Anti-DGP IgG)	0.81		0 0.94 1.05	≤0.94
Deaminated gliadin (Anti-DGP IgA)	0.48		0 0.94 1.05	≤0.94
Immune Health	**Current**	**Previous**	**Result**	**Reference**
Platelet antigens (GPIIb)	<0.25		0 1 1.25	≤1.0
Platelet antigens (GPIIIa)	0.35		0 1 1.25	≤1.0

© Vibrant America Clinical Laboratory (CLIA No. 05D2078809) | 3521 Leonard Ct, Santa Clara, CA 95054
Laboratory Director: Dr. Claude O. Burdick, M.D. | 1-866-364-0963 | Support@vibrant-wellness.com | www.vibrant-wellness.com

Patient Name: **DEMO DEMO**
Date of Birth: **00-00-0000** Accession ID: **2526442383**
Service Date: **Local 2026-03-29 17:00**

Immune Zoomer - All Markers

Immune Zoomer

Immune Health	Current	Previous	Result	Reference
Interferon-α/β receptor 1	0.77		0 1 1.25	≤1.0
Interferon-α/β receptor 2	0.51		0 1 1.25	≤1.0
Joints/Arthritis	**Current**	**Previous**	**Result**	**Reference**
Collagen type II	3.45		0 1 1.25	≤1.0
Rheumatoid Factor (RF) (IU/mL)	25.0		0 14	≤14.0
Citrullinated Peptide Antibodies (CCP3)	21.1		0 19.9 39.9	≤19.9
Kidney	**Current**	**Previous**	**Result**	**Reference**
α-actinin	0.31		0 1 1.25	≤1.0
Liver	**Current**	**Previous**	**Result**	**Reference**
Microsomal antibodies (LKM1)	<0.25		0 1 1.25	≤1.0
Smooth muscle antibodies (ASMA)	<0.25		0 1 1.25	≤1.0
Mixed Connective Tissue	**Current**	**Previous**	**Result**	**Reference**
U1-snRNP 68/70 kDa	0.93		0 1 1.25	≤1.0
U1-snRNP A	<0.25		0 1 1.25	≤1.0
U1-snRNP C	<0.25		0 1 1.25	≤1.0
U1-snRNP B/B'	0.59		0 1 1.25	≤1.0
Muscular System	**Current**	**Previous**	**Result**	**Reference**
Titin	0.72		0 1 1.25	≤1.0
Cardiac myosin	0.64		0 1 1.25	≤1.0
Jo-1 (histidyl-tRNA synthetase)	0.81		0 1 1.25	≤1.0
PM/Scl75	<0.25		0 1 1.25	≤1.0
PM/Scl100	0.44		0 1 1.25	≤1.0

© Vibrant America Clinical Laboratory (CLIA No. 05D2078809) | 3521 Leonard Ct, Santa Clara, CA 95054
Laboratory Director: Dr. Claude O. Burdick, M.D. | 1-866-364-0963 | Support@vibrant-wellness.com | www.vibrant-wellness.com

Patient Name: **DEMO DEMO**
Date of Birth: **00-00-0000** Accession ID: **2526442383**
Service Date: **Local 2026-03-29 17:00**

Immune Zoomer - All Markers

Immune Zoomer

Pancreas	Current	Previous	Result	Reference
Insulin	0.37		0 1 1.25	≤1.0
Islet Cell Antigen 1	<0.25		0 1 1.25	≤1.0
Islet Cell Antigen 2	0.94		0 1 1.25	≤1.0
Glutamic Acid Decarboxylase 65 (GAD65)	0.81		0 1 1.25	≤1.0
Glutamic Acid Decarboxylase 67 (GAD67)	0.52		0 1 1.25	≤1.0

Peripheral Nervous System	Current	Previous	Result	Reference
Ganglioside GM1	<0.25		0 1 1.25	≤1.0
Myelin-associated glycoprotein (MAG)	<0.25		0 1 1.25	≤1.0

Skin	Current	Previous	Result	Reference
Centromere protein (CENP A)	0.35		0 1 1.25	≤1.0
Centromere protein (CENP B)	0.61		0 1 1.25	≤1.0
Desmoglein 1	0.48		0 1 1.25	≤1.0
Desmoglein 2	<0.25		0 1 1.25	≤1.0
Desmoglein 3	<0.25		0 1 1.25	≤1.0
Type VII collagen	0.43		0 1 1.25	≤1.0
Scleroderma-specific antibodies (Scl-70)	0.82		0 1 1.25	≤1.0
RNA Polymerase 3	0.78		0 1 1.25	≤1.0

Systemic Autoimmune	Current	Previous	Result	Reference
Sm antigen	0.41		0 1 1.25	≤1.0
Sm/RNP	0.57		0 1 1.25	≤1.0
SmD	<0.25		0 1 1.25	≤1.0
SmD1	<0.25		0 1 1.25	≤1.0
SmD2	0.44		0 1 1.25	≤1.0

© Vibrant America Clinical Laboratory (CLIA No. 05D2078809) | 3521 Leonard Ct, Santa Clara, CA 95054
Laboratory Director: Dr. Claude O. Burdick, M.D. | 1-866-364-0963 | Support@vibrant-wellness.com | www.vibrant-wellness.com

Patient Name: **DEMO DEMO**
Date of Birth: **00-00-0000** Accession ID: **2526442383**
Service Date: **Local 2026-03-29 17:00**

Immune Zoomer - All Markers

Immune Zoomer

Systemic Autoimmune	Current	Previous	Result	Reference
SmD3	<0.25		0 1 1.25	≤1.0
Nucleosome/Chromatin	0.68		0 1 1.25	≤1.0
Histones	<0.25		0 1 1.25	≤1.0
Double-stranded DNA (dsDNA) (IU/mL)	86.7		0 99.9	≤99.9

Systemic Autoimmune	Current	Pattern	Titer	Previous	Pattern	Titer
Antinuclear Antibodies (ANA)	POSITIVE	Homogeneous	1:320			

Thyroid	Current	Previous	Result	Reference
Thyroglobulin (TG)	64.6		0 115	≤115.0
Thyroid Peroxidase (TPO)	13.0		0 34.9	≤34.9

Inflammation	Current	Previous	Result	Reference
hsCRP	7.4		0 0.9 3	≤0.9

© Vibrant America Clinical Laboratory (CLIA No. 05D2078809) | 3521 Leonard Ct, Santa Clara, CA 95054
Laboratory Director: Dr. Claude O. Burdick, M.D. | 1-866-364-0963 | Support@vibrant-wellness.com | www.vibrant-wellness.com

Risk and Limitations

Test results reflect biological and analytical findings at the time of specimen collection and may vary between individuals. Reference ranges for most of laboratory-developed tests (LDT) were established using a healthy adult population and may not be representative of other specific populations (e.g. pediatric, pregnant, individuals with chronic conditions or from all ethnic backgrounds). They do not provide absolute levels at which the symptoms may occur and hence clinical correlation by the provider is recommended.

Results may be affected by pre-analytical variables related to specimen collection, handling, transport, storage, and inherent biological variability. Specimens including urine, saliva, stool, and blood-based samples (serum, plasma, EDTA whole blood, TES, and dried blood spots) may be impacted by improper collection technique, contamination, insufficient sample volume, delayed shipment or processing, temperature excursions, or improper storage conditions. Additional factors such as hemolysis; anticoagulant effects; clotting, centrifugation, or mixing parameters; incomplete mixing with transport media; and variability in dried blood spot application or saturation may further affect analyte stability or result accuracy. Specimen-specific factors, including urine dilution or concentration, variability in saliva composition or flow rate, and intermittent microbial shedding in stool, may also contribute to result variability. These factors may impact result accuracy and, in some cases, lead to a Test Not Performed (TNP). When clinically appropriate, repeat testing may be recommended; however, repeat testing may still fail to produce a reportable result if the underlying limitations persist.

All laboratory testing methodologies are subject to inherent analytical limitations related to instrument performance, assay design, methodological variability, and the specifications of FDA-approved and laboratory-developed analytes included in a test panel. As with all clinical laboratory testing, there is a small possibility of incorrect results due to technical errors, sample misidentification, contamination, rare genetic variants, or software-related issues.

Genetic testing is helpful in analyzing risks to various diseases. However, it is important to note that genetic risk determinants are neither necessary nor sufficient for the development of disease. Environmental and lifestyle risk factors could also affect the risk of disease development. Genetic risk does not indicate how common a health condition or variant is within the population; a risk-associated variant may be common or uncommon. Interpretation of genetic results should consider individual health context, as population-based reference frameworks may not fully represent all age groups, ethnic backgrounds, or health profiles. Genetic testing evaluates only the genotypes indicated and does not assess other genetic abnormalities found elsewhere in the genome. Different laboratories may test different variants when evaluating genetic risk for a given condition; therefore, genetic risk results may not be directly comparable between laboratories.

Some individuals may experience anxiety related to their genetic test results. Vibrant encourages any concerned individual to consult with a qualified healthcare professional prior to sample collection for a genetic test. Users of the test are encouraged to discuss their test results with a genetic counselor, board-certified clinical molecular geneticist, or equivalent health care professional. In some cases, the identification of risk-associated genetic variants may prompt discussion with a healthcare provider about additional testing or follow-up.

The reported analytes, SNPs, and associated informational content are informed by scientific knowledge at the time of reporting, including peer-reviewed scientific publications, publicly available research, and guidance from recognized scientific and public health organizations. Interpretive content may be updated as scientific knowledge continues to evolve. The informational content included in this report is derived from publicly available scientific literature and is provided for educational and informational purposes only. This content does not replace medical advice from a qualified healthcare professional. Any wellness, nutritional, or dietary recommendations, diagnoses of medical conditions, or treatment decisions based on these results are made at the discretion and responsibility of the ordering healthcare professional.

Vibrant does not diagnose, treat, or cure medical conditions and does not replace the care of a licensed medical practitioner or counselor, nor does Vibrant recommend self-diagnosis or self-medication. Depending on the nature of testing, individuals who receive moderate- or high-risk results may be advised to pursue confirmatory testing and appropriate medical follow-up. Vibrant assumes no liability for any loss, injury, or damages arising from the procurement, compilation, interpretation, delivery, or reporting of information contained in this report, nor from any decisions made or actions taken based on these results.

The supplement recommendations and dosage guidelines provided are intended for general informational purposes only and should not replace professional medical advice; final dosage decisions must be made in consultation with your healthcare provider. Vibrant disclaims any liability for adverse effects, outcomes, or consequences arising from the use of these suggestions.